BPC-157 TB500 Blend for Laboratory Research

BPC-157 TB500 is catalogued under the secondary name Wolverine Blend as a two-component research blend. Its declared composition is 5 mg BPC-157 and 5 mg TB-500, giving 10 mg total declared peptide. The commercial name states no property, and the composition declaration is not a mixture-level experimental finding.

The TB-500 designation does not by itself settle molecular identity. Analytical literature in the source set uses TB-500 for the acetylated fragment Ac-LKKTETQ, whereas wider catalogue usage may refer to full-length, 43-amino-acid thymosin beta-4. The applicable label, specification and batch analytics must identify the form actually present.

Analytical identity context: Esposito et al. 2012 · PMID 22962027

The cards separate the two declared components and their evidence boundaries. All cited findings belong to the stated molecule and experimental model; they neither characterise the combined material nor establish additive or synergistic behaviour.

One publication compares both substances given together: Biçer et al. assigned 32 rats to four groups of eight — control, BPC-157, TB-500 and the combination — in an Achilles tendon repair model and reported no additional benefit for the combined arm over either substance alone (PMID 42542926; rat animal model). No publication tests the declared 5 mg plus 5 mg combination itself. The component publications form separate evidence sets and must not be combined into a claim about BPC-157 TB500.

Component research sources: Huang et al. 2015 · PMID 25995620 · Hsieh et al. 2017 · PMID 27847966 · Chang et al. 2011 · PMID 21030672 · Esposito et al. 2012 · PMID 22962027 · Safer et al. 1991 · PMID 1999398 · Philp et al. 2003 · PMID 12581423

The material is listed internally as lyophilised, but the released records cited by the source do not conclusively establish that form. No temperature, light condition, stability period or shelf-life is asserted here; binding conditions must come from the released label, specification and applicable batch documentation.

An attributable Certificate of Analysis should connect the BPC-157 TB500 product designation, batch code, test date, declared components and methods with the reported findings. Both components and their declared quantities should be accounted for separately.

An HPLC result can describe a chromatographic profile or method-specific purity result only for the batch tested. It does not support a general purity statement and may not by itself establish both identities. Mass-sensitive analysis is especially relevant where the TB-500 assignment must distinguish Ac-LKKTETQ from full-length thymosin beta-4.

Identity distinction informing batch review: Esposito et al. 2012 · PMID 22962027 · Safer et al. 1991 · PMID 1999398

BPC-157 TB500 is supplied to laboratories in the EU as research material under the secondary catalogue name Wolverine Blend. Before assignment to a controlled study, laboratory records should reconcile the product designation, batch code, 5 mg declaration for each component, 10 mg total and the applicable batch documentation.

Published literature in the source set concerns the separate components in analytical, biochemical, cell-based, ex vivo or animal systems, plus one rat model comparing both substances alone and combined; PEG-MGF remains a separate research record. None of it certifies supplied material or establishes a result for the declared blend.

For laboratory research only. Not for human or veterinary use.